On February 17, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, reported that it will present two abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Both abstracts are scheduled for presentation in the Experimental and Molecular Therapeutics category under the session titled Radiopharmaceutical Platforms for Theranostic Precision Oncology on April 21, 2026.
In accordance with AACR (Free AACR Whitepaper) embargo policies, details of the abstracts, including titles and full text, will become publicly available on March 17, 2026, at 4:30 PM ET via the AACR (Free AACR Whitepaper) Online Program Planner.
Presentation Details
Presentation #1:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 18
Poster Number: 5824
Presentation #2:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 21
Poster Number: 5827
Actinium’s Platform Strategy for Long-Term Value Creation
The AACR (Free AACR Whitepaper) 2026 data will highlight Actinium’s differentiated biology-driven approach to targeted radiotherapy development including:
Targeting resistance-associated biology rather than tumor surface expression alone
Leveraging the high-linear energy transfer (LET) of Ac-225 to deliver potent, tumor-specific cytotoxicity
Building a radiotherapy franchise comprised of multiple pan-tumor assets
Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, commented, "We are pleased to have two abstracts accepted for presentation at AACR (Free AACR Whitepaper) 2026. Participation in this meeting provides an important opportunity to engage with the Oncology research community. We look forward to sharing additional details once the abstracts are publicly released in accordance with AACR (Free AACR Whitepaper) guidelines."
(Press release, Actinium Pharmaceuticals, FEB 17, 2026, View Source [SID1234662726])